Paul Baehr

Haemacure Corp. is engaged in the development, marketing and sales of surgical sealants and related medical devices. Its primary product is a fibrin sealant, a tissue sealant comprised of fibrinogen and thrombin extracted from human plasma. The fibrin sealant is used in surgical procedures to arrest bleeding and as an adjunct to wound healing. It was founded on August 19, 1991 and is headquartered in Montreal, Canada.

Transition Therapeutics, Inc. develops novel therapeutics for disease indications. It operates through research and development of therapeutic agents segment. The firm's products include ELND005 for the treatment of alzheimer's disease, bipolar disorder and down syndrome. Its metabolic drug candidate is TT401 for treatment of type 2 diabetes and accompanying obesity. Transition Therapeutics was founded by Tony F. Cruz on July 6, 1998 and is headquartered in Toronto, Canada.

IBEX Technologies, Inc. manufactures and markets enzymes for biomedical use. The firm also specializes in the custom aliquoting, filling, and lyophilization of enzymes in diagnostic disposables for medical devices. Its products include glycobiology enzymes from flavobacterium heparinum, collagen assays, collagen antibodies, and diamine oxidase liquid. The company was founded by Robert A. Heft on April 10, 1972 and is headquartered in Montréal, Canada.

NeuroMedix, Inc. develops pharmaceutical products. The company makes therapeutic agents for the treatment of degenerative and inflammatory diseases of the central nervous system, such as Alzheimer's disease and multiple sclerosis. It also develops therapies for the treatment of other degenerative neuroinflammatory diseases, such as Parkinson's. NeuroMedix was founded in 2005 and is headquartered in Toronto, Canada.

Ciba-Geigy AG was manufacturing pharmaceuticals. The company was merged with Sandoz Ltd. to create Novartis AG. The company was founded in 1884 and was headquartered in Basle, Switzerland.